Immutep Announces Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast | Finance News Network

Media ReleasesImmutep

View All Immutep News


Immutep Announces Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast

SYDNEY, AUSTRALIA – May 30, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced new data from its ongoing TACTI-mel Phase I clinical trial. This study is evaluating the combination of eftilagimod alpha (“efti” or IMP321), Immutep’s lead product, in combination with pembrolizumab (KEYTRUDA®) in unresectable or metastatic melanoma patients that have had a suboptimal response or had disease progression with pembrolizumab monotherapy in the first three cohorts.


For further information please download PDF attached:
Download this document